Atlas Trials

The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

Clinical trial NCT07670182 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07670182
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer
Start date
2026-06-15
Primary completion
2030-10-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.